Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380231 | 0.91 | CNR1 (0.56) | CNR1CNR2GPR119 | |
| SCHEMBL5383708 | 0.86 | CNR1 (0.55) | CNR1CNR2GPR119 | |
| SCHEMBL4837396 | 0.84 | CNR1 (0.47) | CNR1CNR2ALDH1A1 | |
| SCHEMBL5390432 | 0.78 | CNR1 (0.64) | CNR1CNR2GPR119 | |
| SCHEMBL4838496 | 0.77 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL5386529 | 0.76 | CNR1 (0.45) | CNR1CNR2GPR119TDP1 | |
| SCHEMBL4841189 | 0.75 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL5390202 | 0.75 | CNR1 (0.53) | CNR1CNR2THRB | |
| SCHEMBL4842175 | 0.74 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL5608392 | 0.74 | CNR1 (0.43) | CNR1CNR2GPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1594872-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069838-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885GPR119 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.